Vogel Arndt, Kelley Robin K, Johnson Philip, Merle Philippe, Yau Thomas, Kudo Masatoshi, Meyer Tim, Rimassa Lorenza
Department of Klinik für Gastroenterology, Hannover Medical School, Hannover, Germany.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California, USA.
Liver Cancer. 2023 Jan 17;12(4):372-391. doi: 10.1159/000529173. eCollection 2023 Sep.
We conducted a systematic literature review to assess the utility of liver function assessments for predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma (aHCC).
This was a PRISMA-standard review and was registered with PROSPERO (CRD42021244588). MEDLINE and Embase were systematically searched (March 24, 2021) to identify publications reporting the efficacy and/or safety of systemic anticancer therapy (vs. any/no comparator) in liver-function-defined subgroups in phase 2 or 3 aHCC trials. Screening was completed by a single reviewer, with uncertainties resolved by a second reviewer and/or the authors. English-language full-text articles and congress abstracts were eligible for inclusion. Included publications were described and assessed for risk of bias using the GRADE methodology.
Twenty (of 2,579) screened publications were eligible; seven categorized liver function using the albumin-bilirubin system, nine using the Child-Pugh system, four using both. GRADE assessment classified ten, nine, and one publication(s) as reporting moderate-quality, low-quality, and very-low-quality evidence, respectively. Analyses of cross-trial trends of within-exposure arm analyses (active and control) reported a positive relationship between baseline liver function and overall survival and progression-free survival, supporting liver function as a prognostic marker in aHCC. There were also signals for a modest relationship between more preserved baseline liver function and extent of systemic treatment benefit, and with more preserved liver function and lower incidence of safety events.
This review supports liver function as a prognostic variable in aHCC and highlights the value of a priori stratification of patients by baseline liver function in aHCC trials. The predictive value of liver function warrants further study. Findings were limited by the quality of available data.
我们进行了一项系统的文献综述,以评估肝功能评估在预测晚期肝细胞癌(aHCC)患者疾病预后及对全身抗癌治疗反应方面的效用。
这是一项遵循PRISMA标准的综述,并已在PROSPERO(CRD42021244588)注册。我们系统检索了MEDLINE和Embase(截至2021年3月24日),以确定在2期或3期aHCC试验中,报告肝功能定义亚组中全身抗癌治疗(与任何/无对照相比)的疗效和/或安全性的出版物。由一名审阅者完成筛选,不确定性问题由第二名审阅者和/或作者解决。符合纳入标准的为英文全文文章和会议摘要。对纳入的出版物进行描述,并使用GRADE方法评估偏倚风险。
在筛选的2579篇出版物中,有20篇符合条件;7篇使用白蛋白 - 胆红素系统对肝功能进行分类,9篇使用Child - Pugh系统,4篇两者都用。GRADE评估将10篇、9篇和1篇出版物分别归类为报告中等质量、低质量和极低质量证据。对暴露组内分析(治疗组和对照组)的跨试验趋势分析表明,基线肝功能与总生存期和无进展生存期之间呈正相关,支持肝功能作为aHCC的预后标志物。还有迹象表明,基线肝功能保留程度越高与全身治疗获益程度之间存在适度关系,且肝功能保留程度越高,安全事件发生率越低。
本综述支持肝功能作为aHCC的预后变量,并强调了在aHCC试验中根据基线肝功能对患者进行预先分层的价值。肝功能的预测价值值得进一步研究。研究结果受现有数据质量的限制。